<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27120807</article-id><article-id pub-id-type="pmc">5078087</article-id><article-id pub-id-type="publisher-id">8901</article-id><article-id pub-id-type="doi">10.18632/oncotarget.8901</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Passardi</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Scarpi</surname><given-names>Emanuela</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cavanna</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dall'Agata</surname><given-names>Monia</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tassinari</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leo</surname><given-names>Silvana</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bernardini</surname><given-names>Ilaria</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gelsomino</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tamberi</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brandes</surname><given-names>Alba A.</given-names></name><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tenti</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vespignani</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="A11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Frassineti</surname><given-names>Giovanni L.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amadori</surname><given-names>Dino</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Giorgi</surname><given-names>Ugo</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy</aff><aff id="A2"><sup>2</sup> Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy</aff><aff id="A3"><sup>3</sup> Medical Oncology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy</aff><aff id="A4"><sup>4</sup> Department of Oncology, Infermi Hospital, Rimini, Italy</aff><aff id="A5"><sup>5</sup> Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy</aff><aff id="A6"><sup>6</sup> Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy</aff><aff id="A7"><sup>7</sup> Oncology Unit, University Hospital Modena, Modena, Italy</aff><aff id="A8"><sup>8</sup> Oncology Unit, Degli Infermi Hospital, Faenza, Italy</aff><aff id="A9"><sup>9</sup> Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy</aff><aff id="A10"><sup>10</sup> Oncology Pharmacy Laboratory, IRST IRCCS, Meldola, Italy</aff><aff id="A11"><sup>11</sup> IT Service, IRST IRCCS, Meldola, Italy</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Emanuela Scarpi,</italic><email>emanuela.scarpi@irst.emr.it</email></corresp></author-notes><pub-date pub-type="collection"><day>31</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>21</day><month>4</month><year>2016</year></pub-date><volume>7</volume><issue>22</issue><fpage>33210</fpage><lpage>33219</lpage><history><date date-type="received"><day>24</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>4</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Passardi et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>To investigate the role of pre-treatment inflammatory indexes (II) as predictors of prognosis and treatment efficacy in patients with metastatic colorectal cancer mCRC randomized onto the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT) with or without bevacizumab (Bev).</p></sec><sec><title>Results</title><p>In the overall population, PFS and OS were higher in patients with low SII (<italic>p</italic> = .015 and .002, respectively), low NLR (<italic>p</italic> = .0001 and &#x0003c;.0001, respectively) and low PLR (<italic>p</italic> = .004 and .008, respectively). Patients with low NLR in the CT plus Bev arm had a higher PFS than those treated with CT alone (HR = 0.69, <italic>p</italic> = .021).</p></sec><sec><title>Patients and Methods</title><p>Two hundred and eighty-nine patients were considered for this study, 141 receiving CT plus Bev and 148 receiving CT alone. The pre-treatment systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were evaluated to identify a potential correlation with progression-free (PFS) and overall survival (OS) in both the overall population and the 2 treatment arms.</p></sec><sec><title>Conclusion</title><p>Our results indicate that II, in particular NLR, are good prognostic and predictive markers for mCRC patients who are candidates for CT plus Bev.</p></sec></abstract><kwd-group><kwd>metastatic colorectal cancer</kwd><kwd>bevacizumab</kwd><kwd>SII NLR PLR</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Bevacizumab (Bev) is a humanized monoclonal antibody with antiangiogenic activity that binds to the vascular endothelial growth factor (VEGF), leading to the inhibition of the circulating ligand and to the prevention of receptor activation [<xref rid="R1" ref-type="bibr">1</xref>]. The use of Bev combined with fluoropyrimidine-based chemotherapy (CT) is considered standard first-and second-line treatment for patients with metastatic colorectal cancer (mCRC).</p><p>Validated predictors of sensitivity or resistance to Bev are still not available, notwithstanding several studies have investigated this issue in recent years. The majority of these studies focused on the VEGF pathway, including tumor VEGF expression, whereas less attention was paid to the tumor microenvironment and inflammatory response [<xref rid="R2" ref-type="bibr">2</xref>].</p><p>It has increasingly been recognized that tumor infiltrating inflammatory cells are responsible for producing inflammatory mediators and cytokines that induce angiogenesis, tumor growth, invasion and metastasis [<xref rid="R3" ref-type="bibr">3</xref>&#x02019;<xref rid="R5" ref-type="bibr">5</xref>]. Accordingly, serum white blood cells, neutrophils, lymphocytes, platelets and acute-phase proteins, such as C-reactive protein and albumin, have been evaluated in different malignancies and found to predict for prognosis and response to treatment [<xref rid="R6" ref-type="bibr">6</xref>&#x02019;<xref rid="R9" ref-type="bibr">9</xref>]. Moreover, inflammatory indexes (II) obtained with different combinations of these factors, such as neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have been reported to be useful prognostic factors in various malignant solid tumors, including CRC [<xref rid="R10" ref-type="bibr">10</xref>&#x02019;<xref rid="R18" ref-type="bibr">18</xref>]. The systemic immune-inflammation index (SII) was recently investigated as a prognostic marker in several malignancies including renal cell carcinoma, small cell lung cancer and hepatocellular carcinoma [<xref rid="R19" ref-type="bibr">19</xref>&#x02019;<xref rid="R22" ref-type="bibr">22</xref>].</p><p>In light of the close relationship that has emerged between inflammation and angiogenesis, considerable interest has been aroused in the role of II as predictors of the efficacy of Bev [<xref rid="R23" ref-type="bibr">23</xref>]. If validated, these parameters could represent a reproducible, inexpensive and easy method to select candidates for treatment with Bev.</p><p>We investigated the prognostic and predictive role of baseline II (SII, NLR and PLR) in mCRC patients treated with first-line CT with or without Bev in the phase III prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial (EudraCT no. 2007-004539-44 and on <ext-link ext-link-type="uri" xlink:href="ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01878422) [<xref rid="R24" ref-type="bibr">24</xref>].</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Patient population</title><p>Information on pre-treatment II levels was available for 289 of the 370 patients from the ITACa intention-to-treat population; 145 and 144 had low and high SII values, 168 and 121 had low and high NLR values, and 144 and 145 had low and high PLR values, respectively. Baseline characteristics of patients are shown in Table <xref ref-type="table" rid="T1">1</xref>. Patients, divided into groups on the basis of marker cut-offs, were all comparable for age, gender, tumor localization, CT regimen, KRAS status and treatment arm. A higher proportion of patients with high II had a performance status (PS) of 1-2, the high SII and PLR groups included more stage IV tumors at diagnosis, and the high PLR groups had higher grade-tumors.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline patient characteristics (<italic>n</italic> = 289)</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="3" align="left" valign="top" colspan="1">Patient characteristics</th><th colspan="2" align="center" valign="top" rowspan="1">NLR</th><th rowspan="3" align="center" valign="top" colspan="1"><italic>p</italic></th><th colspan="2" align="center" valign="top" rowspan="1">PLR</th><th rowspan="3" align="center" valign="top" colspan="1"><italic>p</italic></th><th colspan="2" align="center" valign="top" rowspan="1">SII</th><th rowspan="3" align="center" valign="top" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">&#x0003c;3</th><th align="center" valign="top" rowspan="1" colspan="1">&#x02265;3</th><th align="center" valign="top" rowspan="1" colspan="1">&#x0003c;169</th><th align="center" valign="top" rowspan="1" colspan="1">&#x02265;169</th><th align="center" valign="top" rowspan="1" colspan="1">&#x0003c;730</th><th align="center" valign="top" rowspan="1" colspan="1">&#x02265;730</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Median age, years (range)</bold></td><td align="center" valign="top" rowspan="1" colspan="1">65 (33-83)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (34-81)</td><td align="center" valign="top" rowspan="1" colspan="1">.662</td><td align="center" valign="top" rowspan="1" colspan="1">66 (33-83)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (34-81)</td><td align="center" valign="top" rowspan="1" colspan="1">.777</td><td align="center" valign="top" rowspan="1" colspan="1">66 (33-83)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (34-81)</td><td align="center" valign="top" rowspan="1" colspan="1">.351</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>Gender</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="middle" rowspan="1" colspan="1">103 (61.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">71 (58.7)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">84 (62.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">90 (58.4)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">85 (58.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">89 (61.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (38.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (41.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">.653</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (37.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">64 (41.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">.593</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (41.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (38.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">.665</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>Performance Status ECOG</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;0</td><td align="center" valign="middle" rowspan="1" colspan="1">148 (88.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (67.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">118 (87.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">112 (72.7)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">127 (87.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">103 (71.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;1-2</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (11.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (32.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; .0001</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (12.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (27.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">.002</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (12.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (28.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">.0007</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>Tumor localisation</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Rectum</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (24.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (29.7)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">33 (24.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (28.6)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">39 (26.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (26.4)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Colon</td><td align="center" valign="middle" rowspan="1" colspan="1">127 (75.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (70.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">.379</td><td align="center" valign="middle" rowspan="1" colspan="1">102 (75.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">110 (71.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">.429</td><td align="center" valign="middle" rowspan="1" colspan="1">106 (73.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">106 (73.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">.922</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>Stage at diagnosis</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I-III</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (27.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (21.2)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">40 (31.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (19.7)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">43 (31.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (18.6)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IV</td><td align="center" valign="middle" rowspan="1" colspan="1">114 (72.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (78.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">.261</td><td align="center" valign="middle" rowspan="1" colspan="1">89 (69.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">118 (80.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">.031</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (68.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">114 (81.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">.012</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>Grade</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;1</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (6.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.4)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">9 (7.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (3.6)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">7 (5.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (5.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;2</td><td align="center" valign="middle" rowspan="1" colspan="1">92 (68.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (56.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">78 (68.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (58.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">82 (66.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">61 (59.2)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;3</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (25.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (39.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.068</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (23.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (38.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (27.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (34.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.482</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>CT regimen</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;FOLFOX4</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (63.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">72 (59.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">77 (57.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">102 (66.2)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">92 (63.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">87 (60.4)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;FOLFIRI</td><td align="center" valign="middle" rowspan="1" colspan="1">61 (36.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (40.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">.548</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (43.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (33.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">.109</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (36.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (39.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">.596</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold><italic>KRAS</italic><bold>status</bold><xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref></bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Wild type</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (61.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (56.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">72 (59.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (59.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">76 (57.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">76 (61.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mutated</td><td align="center" valign="middle" rowspan="1" colspan="1">61 (38.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (44.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">.491</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (41.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (40.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">.968</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (42.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (38.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">.500</td></tr><tr><td align="left" valign="middle" colspan="10" rowspan="1"><bold>ITACa treatment</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;CT+B</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (51.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (45.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">67 (49.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">74 (48.1)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">75 (51.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (45.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;CT</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (48.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (54.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">.399</td><td align="center" valign="middle" rowspan="1" colspan="1">68 (50.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (51.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">.789</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (48.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (54.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">.317</td></tr></tbody></table><table-wrap-foot><fn id="tfn_001"><label>a</label><p>Mandatory as consequence of amendment n. 1 of 3 May, 2009.</p><p>Abbreviations: NRL, neutrophil-to-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic immune-inflammation index; ECOG, Eastern Cooperative Oncology Group; ITACa, Italian Trial in Advanced Colorectal Cancer; CT, chemotherapy; B, bevacizumab; n, number.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2_2"><title>Prognostic value of patient characteristics and II</title><p>Among patient characteristics, univariate analysis showed that PS was the only variable with a significant impact on survival. Patients with PS = 0 had higher median PFS (9.7 <italic>vs.</italic> 6.8 months; HR = 1.60, 95% CI 1.20-2.15; <italic>p</italic> = .001) and OS (24.8 <italic>vs.</italic> 13.7 months; HR = 2.60, 95% CI 1.90-3.56; <italic>p</italic> &#x0003c; .0001) than those with PS =1-2. No other characteristics correlated with survival (<xref ref-type="supplementary-material" rid="SD2">Supplementary Table S1</xref>, available online only). Patients with high NLR had a lower median PFS (7.8 <italic>vs.</italic> 10.2 months, <italic>p</italic> = .0001) and lower median OS (16.8 <italic>vs.</italic> 25.2 months, <italic>p</italic> &#x0003c; .0001) than those with low NLR. Patients with high PLR had a lower median PFS (8.3 <italic>vs.</italic> 10.2 months, <italic>p</italic> = .004) and lower median OS (19.0 <italic>vs.</italic> 25.2 months, <italic>p</italic> = .008) than those with high PLR. Patients with high SII levels had a lower median PFS (8.3 <italic>vs.</italic> 10.1 months, <italic>p</italic> &#x0003c; .015) and lower median OS (19.0 <italic>vs.</italic> 25.4 months, <italic>p</italic> = .002) than those with low SII (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Prognostic value of II in the overall population</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1"/><th rowspan="2" align="center" valign="middle" colspan="1">No. patients</th><th colspan="3" align="center" valign="middle" rowspan="1">PFS</th><th rowspan="2" align="center" valign="middle" colspan="1">HR (95%CI)<xref ref-type="table-fn" rid="tfn_002"><sup>a</sup></xref></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th><th colspan="3" align="center" valign="middle" rowspan="1">OS</th><th rowspan="2" align="center" valign="middle" colspan="1">HR (95% CI)<xref ref-type="table-fn" rid="tfn_002"><sup>a</sup></xref></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">No. events</th><th align="center" valign="middle" rowspan="1" colspan="1">Median PFS (months) (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">No. events</th><th align="center" valign="middle" rowspan="1" colspan="1">Median OS (months) (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Overall</td><td align="center" valign="middle" rowspan="1" colspan="1">289</td><td align="center" valign="middle" rowspan="1" colspan="1">270</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1 (8.4-9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">228</td><td align="center" valign="middle" rowspan="1" colspan="1">21.3 (19.7-24.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLR &#x0003c;3</td><td align="center" valign="middle" rowspan="1" colspan="1">168</td><td align="center" valign="middle" rowspan="1" colspan="1">155</td><td align="center" valign="middle" rowspan="1" colspan="1">10.2 (9.1-11.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">127</td><td align="center" valign="middle" rowspan="1" colspan="1">25.4 (21.8-31.6)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;3</td><td align="center" valign="middle" rowspan="1" colspan="1">121</td><td align="center" valign="middle" rowspan="1" colspan="1">115</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8 (6.3-8.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.58 (1.21-2.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0009</td><td align="center" valign="middle" rowspan="1" colspan="1">101</td><td align="center" valign="middle" rowspan="1" colspan="1">16.8 (13.7-19.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0 .0001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.68 (1.25-2.27)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLR &#x0003c;169</td><td align="center" valign="middle" rowspan="1" colspan="1">144</td><td align="center" valign="middle" rowspan="1" colspan="1">132</td><td align="center" valign="middle" rowspan="1" colspan="1">10.2 (9.1-11.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">111</td><td align="center" valign="middle" rowspan="1" colspan="1">25.2 (21.3-29.2)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;169</td><td align="center" valign="middle" rowspan="1" colspan="1">145</td><td align="center" valign="middle" rowspan="1" colspan="1">138</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3 (6.9-9.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42 (1.09-1.85)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" rowspan="1" colspan="1">117</td><td align="center" valign="middle" rowspan="1" colspan="1">19.0 (16.2-21.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50 (1.13-2.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SII &#x0003c;730</td><td align="center" valign="middle" rowspan="1" colspan="1">145</td><td align="center" valign="middle" rowspan="1" colspan="1">134</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1 (9.0-10.9)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">110</td><td align="center" valign="middle" rowspan="1" colspan="1">25.4 (21.6-29.9)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;730</td><td align="center" valign="middle" rowspan="1" colspan="1">144</td><td align="center" valign="middle" rowspan="1" colspan="1">136</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3 (6.9-9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 (0.89-1.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.265</td><td align="center" valign="middle" rowspan="1" colspan="1">118</td><td align="center" valign="middle" rowspan="1" colspan="1">19.0 (16.2-20.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37 (1.03-1.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td></tr></tbody></table><table-wrap-foot><fn id="tfn_002"><label>a</label><p>adjusted by ITACa treatment, center, CT regimen, KRAS status and baseline characteristics.</p></fn><p>Abbreviations: NRL, neutrophil-to-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic immune-inflammation index; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap><p>In multivariable analysis, a backward elimination approach confirmed NLR, tumor localization and PS as independent predictors of PFS (<italic>p</italic> = .001, .064 and .010, respectively) and OS (<italic>p</italic> &#x0003c; .0001, .006 and &#x0003c; .0001, respectively) (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Multivariable analysis of PFS and OS</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">PFS</th><th colspan="2" align="center" valign="middle" rowspan="1">OS</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">HR (95%CI)</th><th align="center" valign="middle" rowspan="1" colspan="1">p</th><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLR (&#x02265;3 <italic>vs.</italic> &#x0003c;3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.52 (1.07-2.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.020</td><td align="center" valign="middle" rowspan="1" colspan="1">1.78 (1.17-2.70)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLR (&#x02265;169 <italic>vs.</italic> &#x0003c;169)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.38 (0.99-1.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.051</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 (0.89-1.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SII (&#x02265;730 <italic>vs.</italic> &#x0003c;730)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79 (0.53-1.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.226</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 (0.53-1.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.433</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender (male <italic>vs.</italic> female)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97 (0.76-1.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.827</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 (0.79-1.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.767</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECOG PS (1-2 <italic>vs.</italic> 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47 (1.09-1.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">2.52 (1.82-3.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tumor localization (colon <italic>vs.</italic> rectum)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34 (1.01-1.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">1.58 (1.16-2.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CT regimen (FOLFIRI <italic>vs.</italic> FOLFOX4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 (0.98-1.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.076</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23 (0.94-1.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KRAS status (mutated <italic>vs.</italic> wild type)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98 (0.76-1.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.891</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 (0.81-1.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.635</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ITACa treatment (CT+B <italic>vs.</italic> CT)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 (0.66-1.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.162</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 (0.98-1.67)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>After backward procedure:</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLR (&#x02265;3 <italic>vs.</italic> &#x0003c;3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 (1.18-1.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.76 (1.33-2.32)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender (male <italic>vs.</italic> female)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95 (0.74-1.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.677</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 (0.77-1.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.906</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECOG PS (1-2 <italic>vs.</italic> 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.48 (1.10-2.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" rowspan="1" colspan="1">2.51 (1.82-3.47)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tumor localization (colon <italic>vs.</italic> rectum)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 (0.98-1.71)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 (1.13-2.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CT regimen (FOLFIRI <italic>vs.</italic> FOLFOX4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 (0.93-1.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">.167</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 (0.90-1.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">.217</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KRAS status (mutated <italic>vs.</italic> wild type)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.78-1.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">.995</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 (0.82-1.42)</td><td align="center" valign="middle" rowspan="1" colspan="1">.592</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ITACa treatment (CT+B <italic>vs.</italic> CT)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85 (0.66-1.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">.193</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 (0.98-1.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">.064</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NRL, neutrophil-to-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic immune-inflammation index;</p><p>PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group;</p><p>PS, performance status; ITACa, Italian Trial in Advanced Colorectal Cancer; CT, chemotherapy; B, bevacizumab</p></table-wrap-foot></table-wrap></sec><sec id="s2_3"><title>Predictive value of the II</title><p>Results of the impact of treatment (CT plus Bev and CT alone) on PFS and OS according to the analyzed II, together with 95% CI and HR data, are summarized in Table <xref ref-type="table" rid="T4">4</xref>.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Predictive value of II in the CT plus Bev and CT-only treatment arms</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1"/><th rowspan="2" align="center" valign="middle" colspan="1">No. patients</th><th colspan="3" align="center" valign="middle" rowspan="1">PFS</th><th rowspan="2" align="center" valign="middle" colspan="1">HR (95%CI)<xref ref-type="table-fn" rid="tfn_003"><sup>a</sup></xref></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th><th colspan="3" align="center" valign="middle" rowspan="1">OS</th><th rowspan="2" align="center" valign="middle" colspan="1">HR (95% CI)<xref ref-type="table-fn" rid="tfn_003"><sup>a</sup></xref></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">No. events</th><th align="center" valign="middle" rowspan="1" colspan="1">Median PFS (months) (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">No. events</th><th align="center" valign="middle" rowspan="1" colspan="1">Median OS (months) (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLR</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CT+B</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLR &#x0003c;3</td><td align="center" valign="middle" rowspan="1" colspan="1">86</td><td align="center" valign="middle" rowspan="1" colspan="1">77</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 (10.3-14.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">30.4 (22.6-36.1)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;3</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">54</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9 (4.7-9.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.27 (1.53-3.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">12.7 (7.9-15.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">2.48 (1.61-3.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.0001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CT</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLR &#x0003c;3</td><td align="center" valign="middle" rowspan="1" colspan="1">82</td><td align="center" valign="middle" rowspan="1" colspan="1">78</td><td align="center" valign="middle" rowspan="1" colspan="1">8.9 (7.2-9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">62</td><td align="center" valign="middle" rowspan="1" colspan="1">24.3 (20.2-28.0)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;3</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">8.0 (6.2-9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.315</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.77-1.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.556</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="center" valign="middle" rowspan="1" colspan="1">21.3 (16.8-24.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.143</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 (0.78-1.81)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.415</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLR</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CT+B</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLR &#x0003c;169</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td><td align="center" valign="middle" rowspan="1" colspan="1">11.4 (9.8-13.4)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">27.0 (20.6-34.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;169</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td><td align="center" valign="middle" rowspan="1" colspan="1">8.8 (6.4-9.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 (1.09-2.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td><td align="center" valign="middle" rowspan="1" colspan="1">15.9 (12.9-20.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67 (1.09-2.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CT</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLR &#x0003c;169</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">9.3 (8.3-10.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">24.8 (20.3-29.2)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;169</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">7.3 (5.5-8.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.158</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 (0.88-1.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.214</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">20.4 (16.8-24.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.106</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39 (0.93-2.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.105</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SII</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CT+B</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SII &#x0003c;730</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">11.5 (9.8-13.2)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">58</td><td align="center" valign="middle" rowspan="1" colspan="1">27.4 (21.8-34.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;730</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6 (6.4-9.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 (0.97-2.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">15.1 (11.6-19.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">1.68 (1.10-2.57)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CT</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SII &#x0003c;730</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">9.0 (7.0-9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">24.8 (20.2-29.9)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;730</td><td align="center" valign="middle" rowspan="1" colspan="1">78</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td><td align="center" valign="middle" rowspan="1" colspan="1">8.1 (6.5-9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.408</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 (0.70-1.42)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.978</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">20.4 (17.1-24.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.114</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (0.80-1.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.369</td></tr></tbody></table><table-wrap-foot><fn id="tfn_003"><label>a</label><p>adjusted by ITACa treatment, center, CT regimen, KRAS status and baseline characteristics.</p></fn><p>Abbreviations: NRL, neutrophil-to-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic immune-inflammation index; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CT, chemotherapy; B, bevacizumab.</p></table-wrap-foot></table-wrap></sec><sec id="s2_4"><title>SII</title><p>Median PFS in the CT plus Bev group was 11.5 (95% CI 9.8-13.2) and 8.6 (95% CI 6.4-9.9) months in patients with low and high SII, respectively (<italic>p</italic> = .014), while in the CT-only arm it was 9.0 (95% CI 7.0-9.8) and 8.1 (95% CI 6.5-9.1) months in patients with low and high SII, respectively (<italic>p</italic> = .408). Median OS was significantly associated with SII levels in the CT plus Bev group (27.4 <italic>vs.</italic>15.1 months in low and high SII patients, respectively, <italic>p</italic> = .002), but not in the CT-only arm (24.8 <italic>vs.</italic> 20.4 months, <italic>p</italic> = .114). The interaction test did not reveal a significant correlation between SII levels on the basis of cut-off and treatment for either PFS or OS (<italic>p</italic> = .290 and .279, respectively). In contrast, the evaluation of SII as a continuous variable showed a positive interaction test for both PFS (<italic>p</italic> = .033) and OS (<italic>p</italic> = .043).</p></sec><sec id="s2_5"><title>NLR</title><p>In the CT plus Bev group, median PFS was 12.4 (95% CI 10.3-14.0) and 6.9 (95% CI 4.7-9.0) months in patients with low and high NLR, respectively (<italic>p</italic> &#x0003c; .0001), and median OS was 30.4 (95% CI 22.6-36.1) and 12.7 (95% CI 7.9-15.3), respectively (<italic>p</italic> &#x0003c; .0001). In the CT-only arm, median PFS was 8.9 (95% CI 7.2-9.8) and 8.0 (95% CI 6.2-9.1) months in patients with low and high NLR, respectively (<italic>p</italic> = .315), and median OS was 24.3 (95% CI 20.2-28.0) and 21.3 (95% CI 16.8-24.5), respectively (<italic>p</italic> = .143).</p><p>The interaction test involving NLR levels and the effect of treatment in either group suggested that the correlation between NLR levels and improved outcome was significantly associated with the addition of Bev for both PFS (HR 1.75; 95% CI 1.08-2.84; <italic>p</italic> = .024) and OS (HR = 1.90; 95% CI 1.12-3.22; <italic>p</italic> = .017). This association was confirmed by evaluating the index as a continuous variable (PFS, <italic>p</italic> = .022; OS, <italic>p</italic> = .013).</p></sec><sec id="s2_6"><title>PLR</title><p>In the CT plus Bev group, median PFS was 11.4 (95% CI 9.8-13.4) and 8.8 (95% CI 6.4-9.9) months in patients with low and high PLR, respectively (<italic>p</italic> = .006), and median OS was 27.0 and 15.9 months (<italic>p</italic> = .061). In the CT-only arm, median PFS was 9.3 (95% CI 8.3-10.3) and 7.3 (95% CI 5.5-8.9) months in patients with low and high PLR, respectively (<italic>p</italic> = .158), and median OS was 24.8 and 20.4 months, respectively (<italic>p</italic> = .106). The interaction tests, which considered the cut-off or the continuous variable, did not show any significant correlation between PLR levels and the effect of Bev on outcome (data not shown).</p></sec><sec id="s2_7"><title>Efficacy of Bev as a function of II</title><p>The effect of adding Bev to CT as a function of II was also investigated. Among patients with low SII, a higher, albeit non significant, PFS was observed in those treated with CT plus Bev than in those receiving CT alone (HR = 0.74, 95% CI 0.52-1.04; <italic>p</italic> = .079). In high SII patients, PFS did not differ between the 2 treatment arms (HR = 0.97, 95% CI 0.69-1.36; <italic>p</italic> = .852) (Figure <xref ref-type="fig" rid="F1">1</xref>). Treatment with Bev did not lead to improved OS in patients with either high or low SII values (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>, available online only). Patients with low NLR in the CT plus Bev arm had a higher PFS than those treated with CT alone (HR 0.69, 95% CI 0.50-0.94, <italic>p</italic> = .021) (Figure <xref ref-type="fig" rid="F2">2</xref>), while Bev-treated patients with high NLR had a poorer OS than those receiving CT alone (HR = 1.69, 95% CI 1.14-2.51, <italic>p</italic> = .009) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>, available online only).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Kaplan-Meier curves of progression-free survival according to treatment as a function of SII</title></caption><graphic xlink:href="oncotarget-07-33210-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Kaplan-Meier curves of progression-free survival according to treatment as a function of NLR</title></caption><graphic xlink:href="oncotarget-07-33210-g002"/></fig><p>Patients with low PLR baseline values in the CT plus Bev arm had a trend towards higher PFS than those in the CT-only arm (HR = 0.74, 95% CI 0.53-1.05; <italic>p</italic> = .090), while those with high PLR showed a similar PFS in both treatment arms (HR = 0.93, 95% CI 0.67-1.31; <italic>p</italic> = .691) (Figure <xref ref-type="fig" rid="F3">3</xref>). OS was not affected by the addition of Bev in patients with either high or low PLR values (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S3</xref>, available online only).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Kaplan-Meier curves of progression-free survival according to treatment as a function of PLR</title></caption><graphic xlink:href="oncotarget-07-33210-g003"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>Inflammation produced by the secretion of cytokines and chemokines promotes tumor growth, angiogenesis and metastasis [<xref rid="R3" ref-type="bibr">3</xref>]. Several studies have shown that platelets induce circulating tumor cell epithelial-mesenchymal transition and promote extravasation to metastatic sites [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>]. Neutrophils promote adhesion and seeding of distant organ sites through the secretion of circulating growth factors such as VEGF and proteases [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. Lymphocytes play a crucial role in tumor defense by inducing cytotoxic cell death and inhibiting tumor cell proliferation and migration, thereby dictating the host's immune response to malignancy [<xref rid="R29" ref-type="bibr">29</xref>]. Thus, inflammation induces changes in the cancer microenvironment that favor cancer progression.</p><p>In light of this, several II have been investigated as possible predictors of prognosis and response to treatment in different tumor types. Among these, NLR and PLR represent the most common indices [<xref rid="R10" ref-type="bibr">10</xref>&#x02019;<xref rid="R18" ref-type="bibr">18</xref>], while the SII was only recently introduced [<xref rid="R19" ref-type="bibr">19</xref>&#x02019;<xref rid="R22" ref-type="bibr">22</xref>]. Compared with other potential markers, the measurement of these parameters has the advantage of being inexpensive and reproducible.</p><p>The aim of our study was to evaluate the potential usefulness of these II to estimate prognosis and to predict the efficacy of treatment with Bev. Univariate analysis in the overall population showed that, in addition to performance status, SII, NLR, and PLR were significantly associated with PFS and OS, whereas in multivariate analysis, only ECOG PS and NLR remained markers of PFS and OS.</p><p>The impact of adding Bev to CT differed on the basis of the II and the incorporation (PLR and SII) or not (NLR) of the platelet count. In the present study, NLR appeared to be the most powerful indicator of prognosis. Patients with high NLR treated with Bev had a poorer OS than those treated with CT alone, whereas the addition of Bev did not lead to any significant difference in OS in the SII or PLR groups. Moreover, patients with low NLR in the CT plus Bev arm had a higher PFS than those treated with CT alone.</p><p>In addition to promoting tumor angiogenesis, there is evidence that VEGF favors tumor immune evasion and immune response suppression through different mechanisms mainly regulated by myeloid-derived suppressor cells (MDSCs) [<xref rid="R30" ref-type="bibr">30</xref>]. Bev, as an anti-VEGF agent, may thus induce immune response through several mechanisms including increased trafficking of T cells into tumors, reduction of suppressive cytokines and tumor-infiltrating T regulatory cells and MDSCs, increased CD8+ and CD4+ central memory T cells, and reduced frequency of MDSCs [<xref rid="R31" ref-type="bibr">31</xref>&#x02019;<xref rid="R34" ref-type="bibr">34</xref>]. Whilst the inhibition of VEGF signaling appears to enhance CT efficacy in front-line treatment of patients with low II, high NLR is associated with a poor prognosis and may be correlated with a detrimental immunological effect of Bev. Overall, the role of VEGF in the immune response and its critical role in CRC pathogenesis may represent a rationale to test whether the inhibition of the PD-L1/PD-1 pathway by immune checkpoint inhibitors in combination with anti-VEGF therapies enhances clinical response in mCRC patients. The combined use of II and histological biomarkers (<italic>e.g.</italic> PDL1 expression) could help to select suitable candidates for these treatments.</p><p>In conclusion, II are powerful prognostic and predictive indicators of poor outcome in mCRC patients treated with CT +/&#x02212; Bev. The addition of Bev to CT only appears to improve clinical outcome in those with favorable II values. Validation in a larger prospective data set is warranted.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Patient population and treatment regimens</title><p>Two hundred and eighty-nine patients enrolled onto the first-line ITACa trial were considered. The study design and key eligibility and exclusion criteria have previously been described in detail [<xref rid="R24" ref-type="bibr">24</xref>]. Patients were recruited from 14<sup>th</sup> November 2007 to 6<sup>th</sup> March 2012 and followed up until 31<sup>st</sup> December 2013. After randomization, 176 patients underwent CT (either FOLFIRI or FOLFOX4) plus Bev, while 194 patients received CT alone. Patients were treated until disease progression or unacceptable toxicity occurred. All patients provided written informed consent. The study was carried out in accordance with the Declaration of Helsinki under good clinical practice conditions and after ethics committee approval of all participating centers. Tumor response was radiologically evaluated every 8 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST) until disease progression or withdrawal. The primary endpoint of the trial was progression-free survival (PFS) and secondary endpoints included overall survival (OS).</p><p>Information on neutrophil, lymphocyte and platelet counts from blood tests carried out at baseline (before systemic treatment) was collected. SII was calculated as platelet count &#x000d7; neutrophil count/lymphocyte count, NLR was obtained by dividing the absolute neutrophil count by the absolute lymphocyte count, and PLR was calculated as the ratio of absolute platelet count to absolute lymphocyte count.</p></sec><sec id="s4_2"><title>Statistical analysis</title><p>The aim of this secondary analysis was to examine the association between baseline II levels and PFS and OS in the overall population, and separately in the 2 treatment arms. The data cut-off for analysis was 31<sup>st</sup> December 2013 when the median duration of follow-up was 36 months (range 1-65). PFS was defined as the time from random assignment to the first documentation of PD (per investigator assessment), or death from any cause. Patients undergoing curative metastasectomy were censored at the time of surgery. OS was defined as the time interval between random assignment and death or last follow-up visit. PFS and OS were estimated by the Kaplan-Meier method and curves were compared by the log-rank test (at a significance level of 5%). Estimated hazard ratios (HRs) and their two-sided 95% Confidence Intervals (95% CI) were calculated using the Cox proportional-hazard model. HRs adjusted by center and baseline characteristics (gender, age, ECOG performance status, <italic>KRAS</italic> status, tumor localization (rectum/colon) and CT regimen (FOLFOX4/FOLFIRI) were calculated using the Cox proportional hazards model. Covariate selection was based on a list of suspected prognostic factors derived from the ITACa study [<xref rid="R24" ref-type="bibr">24</xref>].</p><p>The effect of the interaction between II levels and treatment on PFS/OS was evaluated using Cox regression models for the entire population (CT+B and CT-only arms) including II levels, treatment and treatment-by-II levels. X-tile 3.6.1 software (Yale University, New Haven, CT) was used for bioinformatic analysis of baseline data to determine the cutoff value for pre-treatment levels of each II. SII &#x02265;730, NLR &#x02265;3 and PLR &#x02265;169 were considered as elevated levels.</p><p>All <italic>p</italic> values were based on two-sided testing and statistical analyses were performed using SAS statistical software version 9.4 (SAS Inc., Cary, NC, USA).</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY FIGURES AND TABLE</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-07-33210-s001.pdf" orientation="portrait" xlink:type="simple" id="d36e2150" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="doc" xlink:href="oncotarget-07-33210-s002.doc" orientation="portrait" xlink:type="simple" id="d36e2152" position="anchor"/></supplementary-material></sec></body><back><ack><p>The authors thank Ursula Elbling for editorial assistance and Camilla Di Nunzio, Maria Angela Palladino (Piacenza), Caterina Accettura, Luciana Petrucelli, Abbondanza Gambino, Laura Lupo, Valeria Saracino (Lecce), Antonella Pasqualini, Giorgia Razzini (Carpi), Annalisa Fontana (Modena), Angela Ragazzini (Meldola), Britt Rudnas (Rimini), Barbara Venturini (Cattolica), Alessandra Piancastelli (Lugo), Bernadette Vertogen, Federica Zumaglini (Ravenna), Rosalba Poggi, Enrico Franceschi and Stefania Bartolini (Bologna) for participating in this study.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFICTS OF INTEREST</bold></p><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>This trial was partially supported by the Italian Medicines Agency (AIFA - research grant no. FARM6FJJAY).</p></fn><fn fn-type="con"><p><bold>Authors' contributions</bold></p><p>AP, ES, UD conceived and designed the study, performed the analyses, interpreted data and drafted the article. All authors were involved in data acquisition and in revising the manuscript. All gave their approval for the present version of the manuscript to be submitted for publication.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name></person-group><article-title>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</article-title><source>Nat Rev Drug Discov</source><year>2004</year><volume>3</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">15136787</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>de Haas</surname><given-names>S</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Scherer</surname><given-names>SJ</given-names></name></person-group><article-title>Markers of response for the antiangiogenic agent bevacizumab</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">23401453</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Balkwill</surname><given-names>F</given-names></name></person-group><article-title>Cancer-related inflammation</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">18650914</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name></person-group><article-title>Inflammation, a key event in cancer development</article-title><source>Mol Cancer Res</source><year>2006</year><volume>4</volume><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">16603636</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusumanto</surname><given-names>YH</given-names></name><name><surname>Dam</surname><given-names>WA</given-names></name><name><surname>Hospers</surname><given-names>GA</given-names></name><name><surname>Meijer</surname><given-names>C</given-names></name><name><surname>Mulder</surname><given-names>NH</given-names></name></person-group><article-title>Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor</article-title><source>Angiogenesis</source><year>2003</year><volume>6</volume><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">15166496</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozoe</surname><given-names>T</given-names></name><name><surname>Matsumata</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>M</given-names></name><name><surname>Sugimachi</surname><given-names>K</given-names></name></person-group><article-title>Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer</article-title><source>Am J Surg</source><year>1998</year><volume>176</volume><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">9817250</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toiyama</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Saigusa</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>M</given-names></name><name><surname>Kawamoto</surname><given-names>A</given-names></name><name><surname>Okugawa</surname><given-names>Y</given-names></name><name><surname>Hiro</surname><given-names>J</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Mohri</surname><given-names>Y</given-names></name><name><surname>Kusunoki</surname><given-names>M</given-names></name></person-group><article-title>C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery</article-title><source>Anticancer Res</source><year>2013</year><volume>33</volume><fpage>5065</fpage><lpage>5074</lpage><pub-id pub-id-type="pmid">24222151</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibutani</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Nagahara</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>E</given-names></name><name><surname>Ohtani</surname><given-names>H</given-names></name><name><surname>Nishiguchi</surname><given-names>Y</given-names></name><name><surname>Hirakawa</surname><given-names>K</given-names></name></person-group><article-title>Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer</article-title><source>Surg Today</source><year>2015</year><volume>45</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">24817059</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillem-Llobat</surname><given-names>P</given-names></name><name><surname>Dovizio</surname><given-names>M</given-names></name><name><surname>Alberti</surname><given-names>S</given-names></name><name><surname>Bruno</surname><given-names>A</given-names></name><name><surname>Patrignani</surname><given-names>P</given-names></name></person-group><article-title>Platelets, cyclooxygenases, and colon cancer</article-title><source>Semin Oncol</source><year>2014</year><volume>41</volume><fpage>385</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">25023354</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>SR</given-names></name><name><surname>Cook</surname><given-names>EJ</given-names></name><name><surname>Goulder</surname><given-names>F</given-names></name><name><surname>Justin</surname><given-names>TA</given-names></name><name><surname>Keeling</surname><given-names>NJ</given-names></name></person-group><article-title>Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer</article-title><source>J Surg Oncol</source><year>2005</year><volume>91</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">16118772</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>Y</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Chun</surname><given-names>YS</given-names></name><name><surname>Palavecino</surname><given-names>M</given-names></name><name><surname>Abdalla</surname><given-names>EK</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name></person-group><article-title>Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy</article-title><source>Ann Surg Oncol</source><year>2009</year><volume>16</volume><fpage>614</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">19130139</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>W</given-names></name><name><surname>Charles</surname><given-names>KA</given-names></name><name><surname>Baracos</surname><given-names>VE</given-names></name><name><surname>Clarke</surname><given-names>SJ</given-names></name></person-group><article-title>Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer</article-title><source>Br J Cancer</source><year>2011</year><volume>104</volume><fpage>1288</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">21448173</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Oh</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>KJ</given-names></name><name><surname>Roh</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer</article-title><source>Biomarkers</source><year>2012</year><volume>17</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">22424597</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proctor</surname><given-names>MJ</given-names></name><name><surname>McMilan</surname><given-names>DC</given-names></name><name><surname>Morrison</surname><given-names>DS</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>Clarke</surname><given-names>SJ</given-names></name></person-group><article-title>A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer</article-title><source>Br J Cancer</source><year>2012</year><volume>107</volume><fpage>695</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">22828611</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibutani</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Nagahara</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>E</given-names></name><name><surname>Ohtani</surname><given-names>H</given-names></name><name><surname>Nishiguchi</surname><given-names>Y</given-names></name><name><surname>Hirakawa</surname><given-names>K</given-names></name></person-group><article-title>A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer</article-title><source>Anticancer Res</source><year>2013</year><volume>33</volume><fpage>3291</fpage><lpage>3294</lpage><pub-id pub-id-type="pmid">23898094</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MX</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Zhang</surname><given-names>JF</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>ZW</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name></person-group><article-title>Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><fpage>2403</fpage><lpage>2413</lpage><pub-id pub-id-type="pmid">24122750</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>McNamara</surname><given-names>MG</given-names></name><name><surname>Seruga</surname><given-names>B</given-names></name><name><surname>Vera-Badillo</surname><given-names>FE</given-names></name><name><surname>Aneja</surname><given-names>P</given-names></name><name><surname>Oca&#x000f1;a</surname><given-names>A</given-names></name><name><surname>Leibowitz-Amit</surname><given-names>R</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name><name><surname>Knox</surname><given-names>JJ</given-names></name><name><surname>Tran</surname><given-names>B</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>Amir</surname><given-names>E</given-names></name></person-group><article-title>Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta analysis</article-title><source>J Natl Cancer Inst</source><year>2014</year><volume>106</volume><fpage>dju124</fpage><pub-id pub-id-type="pmid">24875653</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Shibutani</surname><given-names>M</given-names></name><name><surname>Otani</surname><given-names>H</given-names></name><name><surname>Nagahara</surname><given-names>H</given-names></name><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Ikeya</surname><given-names>T</given-names></name><name><surname>Amano</surname><given-names>R</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>N</given-names></name><name><surname>Muguruma</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prognostic value of preoperative inflammation-based prognostic scores in patients with stage IV colorectal cancer who undergo palliative resection of asymptomatic primary tumors</article-title><source>Anticancer Res</source><year>2013</year><volume>33</volume><fpage>5567</fpage><lpage>5573</lpage><pub-id pub-id-type="pmid">24324099</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>XR</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>YF</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>WM</given-names></name><name><surname>Qiu</surname><given-names>SJ</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>6212</fpage><lpage>6222</lpage><pub-id pub-id-type="pmid">25271081</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name></person-group><article-title>Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer</article-title><source>Tohoku J Exp Med</source><year>2015</year><volume>236</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">26250537</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>43090</fpage><lpage>43098</lpage><pub-id pub-id-type="pmid">26506519</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Giorgi</surname><given-names>U</given-names></name><name><surname>Maruzzo</surname><given-names>M</given-names></name><name><surname>Santoni</surname><given-names>M</given-names></name><name><surname>Massari</surname><given-names>F</given-names></name><name><surname>Wheater</surname><given-names>MJ</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name><name><surname>Lolli</surname><given-names>C</given-names></name><name><surname>Sotte</surname><given-names>V</given-names></name><name><surname>Crabb</surname><given-names>SJ</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Basso</surname><given-names>U</given-names></name><name><surname>Schepisi</surname><given-names>G</given-names></name></person-group><article-title>Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><comment>(suppl; abstr e15595) submitted</comment></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Burge</surname><given-names>M</given-names></name><name><surname>Cordwell</surname><given-names>C</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name><name><surname>Reece</surname><given-names>W</given-names></name><name><surname>Tebbutt</surname><given-names>N</given-names></name></person-group><article-title>An australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab (Avastin) [ASCENT]</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>120</fpage><pub-id pub-id-type="pmid">23497305</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passardi</surname><given-names>A</given-names></name><name><surname>Nanni</surname><given-names>O</given-names></name><name><surname>Tassinari</surname><given-names>D</given-names></name><name><surname>Turci</surname><given-names>D</given-names></name><name><surname>Cavanna</surname><given-names>L</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Ruscelli</surname><given-names>S</given-names></name><name><surname>Mucciarini</surname><given-names>C</given-names></name><name><surname>Lorusso</surname><given-names>V</given-names></name><name><surname>Ragazzini</surname><given-names>A</given-names></name><name><surname>Frassineti</surname><given-names>GL</given-names></name><name><surname>Amadori</surname><given-names>D</given-names></name></person-group><article-title>Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><fpage>1201</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">25735317</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labelle</surname><given-names>M</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>Direct signaling between platelets and cancer cells induces epithelial-mesenchymal-like transition and promote metastasis</article-title><source>Cancer Cell</source><year>2011</year><volume>20</volume><fpage>576</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">22094253</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>D</given-names></name><name><surname>Strilic</surname><given-names>B</given-names></name><name><surname>Sivaraj</surname><given-names>KK</given-names></name><name><surname>Wettschureck</surname><given-names>N</given-names></name><name><surname>Offermanns</surname><given-names>S</given-names></name></person-group><article-title>Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor</article-title><source>Cancer Cell</source><year>2013</year><volume>24</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">23810565</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools-Lartigue</surname><given-names>J</given-names></name><name><surname>Spicer</surname><given-names>J</given-names></name><name><surname>McDonald</surname><given-names>B</given-names></name><name><surname>Gowing</surname><given-names>S</given-names></name><name><surname>Chow</surname><given-names>S</given-names></name><name><surname>Giannias</surname><given-names>B</given-names></name><name><surname>Bourdeau</surname><given-names>F</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name><name><surname>Ferri</surname><given-names>L</given-names></name></person-group><article-title>Neutrophyl extracellular traps sequester circulating tumor cells and promote metastasis</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>3446</fpage><lpage>3458</lpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Santoni</surname><given-names>M</given-names></name><name><surname>Crabb</surname><given-names>SJ</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name><name><surname>Burattini</surname><given-names>L</given-names></name><name><surname>Chau</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>E</given-names></name><name><surname>Savini</surname><given-names>A</given-names></name><name><surname>Burgio</surname><given-names>SL</given-names></name><name><surname>Conti</surname><given-names>A</given-names></name><name><surname>Conteduca</surname><given-names>V</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>De Giorgi</surname><given-names>U</given-names></name></person-group><article-title>High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer</article-title><source>Ann Surg Oncol</source><year>2015</year><volume>22</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">25234022</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Giorgi</surname><given-names>U</given-names></name><name><surname>Mego</surname><given-names>M</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name><name><surname>Giuliano</surname><given-names>M</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Reuben</surname><given-names>JM</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name></person-group><article-title>Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer</article-title><source>Clin Breast Cancer</source><year>2012</year><volume>12</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">22591634</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name></person-group><article-title>Coordinated regulation of myeloid cells by tumours</article-title><source>Nat Rev Immunol</source><year>2012</year><volume>12</volume><fpage>253</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">22437938</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Lezcano</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sasada</surname><given-names>T</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Giobbie-Hurder</surname><given-names>A</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Friedlander</surname><given-names>P</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Bevacizumab plus ipilimumab in patients with metastatic melanoma</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><fpage>632</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">24838938</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>EA</given-names></name><name><surname>Ullman</surname><given-names>JG</given-names></name><name><surname>Leatherman</surname><given-names>JM</given-names></name><name><surname>Asquith</surname><given-names>JM</given-names></name><name><surname>Hansen</surname><given-names>TR</given-names></name><name><surname>Armstrong</surname><given-names>TD</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Emens</surname><given-names>LA</given-names></name></person-group><article-title>A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>3951</fpage><lpage>3959</lpage><pub-id pub-id-type="pmid">17606729</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roland</surname><given-names>CL</given-names></name><name><surname>Lynn</surname><given-names>KD</given-names></name><name><surname>Toombs</surname><given-names>JE</given-names></name><name><surname>Dineen</surname><given-names>SP</given-names></name><name><surname>Udugamasooriya</surname><given-names>DG</given-names></name><name><surname>Brekken</surname><given-names>RA</given-names></name></person-group><article-title>Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e7669</fpage><pub-id pub-id-type="pmid">19888452</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrimali</surname><given-names>RK</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Theoret</surname><given-names>MR</given-names></name><name><surname>Chinnasamy</surname><given-names>D</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>6171</fpage><lpage>6180</lpage><pub-id pub-id-type="pmid">20631075</pub-id></element-citation></ref></ref-list></back></article>